Informed Prostate Cancer Patient Support

Patient survey re active surveillance | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net Patient survey re active surveillance 2-3 minutes Posted on May 31, 2021 by Sitemaster AnCan, UsTOO, and Active Surveillance Patients International (ASPI) are working together to conduct a survey of the experiences of men who are on active surveillance (AS), have ever considered AS, or were at one time on AS. Spouses/partners of such men are also able to participate. They are interested in getting people to complete this survey as soon as is reasonably possible — ideally by the end of the current week. Here is some detailed information provided by AnCan: AnCan recognizes the AS community has particular needs that are often left unrecognized by both healthcare providers and support groups. In an effort to address that need, and to p

FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK : In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® … prostatecancerinfolink.net FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer 2-3 minutes Posted on May 31, 2021 by Sitemaster In ,a recent media release , Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify ® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. This agent is actually approved for use in two types of patient: men

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis | Prostate Cancer and Prostatic Diseases

Radiogenomics in prostate cancer evaluation : Current Opinion in Urology ARTIFICIAL INTELLIGENCE IN UROLOGY : Edited by Karim Bensalah and Benjamin Pradere Radiogenomics in prostate cancer evaluation Thenault, Ronan a ; Gasmi, Anis a ; Khene, Zine-Edine a ; Bensalah, Karim a ; Mathieu, Romain a,b Author Information Current Opinion in Urology : July 2021 - Volume 31 - Issue 4 - p 424-429 doi: 10.1097/MOU.0000000000000902 Buy Abstract Purpose of review  Radiogenomics, fusion between radiomics and genomics, represents a new field of research to improve cancer comprehension and evaluation. In this review, we give an overview of radiogenomics and its most recent and relevant applications in prostate cancer management. Recent findings  Literature about radiogenomics in prostate cancer emerged last 5 years but remains scarce. Radiogenomics in prostate cancer mainly rely on MRI-based features. Several imaging biomarke

Advances in PSMA-targeted therapy for prostate cancer | Prostate Cancer and Prostatic Diseases

PYLARIFY PSMA PET Scan FDA Approved for Prostate Cancer — Cancer ABCs PSMA PET Scan , PLY PSMA , PSMA Scan As many of you may know, the FDA approved the  Gallium 68 PET Scan  in December 2020, although it is currently only available in Los Angles, and San Francisco.   We now have a second  PSMA PET Scan  that has been approved by the FDA.    This new PSMA scan, approved on May 26th,   2021, is called  PYLARIFY (or PyL) .  This Scan will be available very quickly in “Mid-Atlantic and southern regions” of the US, but not widely available for a while in other areas of the country, as the company (Progenics/ Lantheus) will need to ramp up their production abilities. We believe that this new PSMA scan will become widely obtainable throughout the US, by the end of 2021.    Watch this blog, or  www.lantheus.com  for updates.    Both of the approved PSMA PET Scans are approved for two types of prostate cancer patients: • “…with sus

FDA OKs New PSMA-PET Tracer for Prostate Cancer Detection | MedPage Today medpagetoday.com FDA OKs New PSMA-PET Tracer for Prostate Cancer Detection by Mike Bassett, Staff Writer, MedPage Today May 27, 2021 3-4 minutes Oncology/Hematology > Prostate Cancer — Piflufolastat F 18 to be commercially available across entire U.S. by year's end, drugmaker says The FDA on Thursday approved piflufolastat F 18 (Pylarify), a prostate-specific membrane antigen (PSMA) PET imaging agent for the detection of prostate cancer, Lantheus Holdings announced . Piflufolastat F 18 is indicated for use in men with suspected metastasis who are candidates for initial definitive therapy or for those with biochemical recurrence base

The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosi... : Medicine Research Article: Systematic Review and Meta-Analysis The meta-analysis of the effect of 68 Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan Zhao, Ruining MD a,∗ ; Li, Yajie MS a ; Nie, Lihong PhD b ; Qin, Kaiyue MS b ; Zhang, Hang MS a ; Shi, Hongbin MS a Editor(s): Ding., Jianxun Author Information Medicine: April 16, 2021 - Volume 100 - Issue 15 - p e25417 doi: 10.1097/MD.0000000000025417 Open Abstract Background:  68 Ga-PSMA-PET/CT (positron emission tomography/computed tomography) is a promising method for prostate cancer (PC) detection. However, the ability of 68 Ga-PSMA-PET/CT to detect malignant bone lesions, and whether this method is superior to the existing bone imaging methods are still lack of systematic analysis. Purpose:  To evaluate the value of 68 Ga-PSMA-PET/CT and bone scan in clinical diagno

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients - Zhu - - The Prostate - Wiley Online Library ORIGINAL ARTICLE Open Access Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients Sha Zhu MM , Junru Chen MM , Yuchao Ni MB , Haoran Zhang MD , Zhenhua Liu MD , Pengfei Shen MD , Guangxi Sun MD , Jiayu Liang MD , Xingming Zhang MD , Zhipeng Wang MM … See all authors First published: 24 May 2021 https://doi.org/10.1002/pros.24167 Abstract Background Multidisciplinary team (MDT) management is a popular treatment paradigm in managing cancer patients, which provides fully-discussed, interdisciplinary treatment reco

The Telomere Length Landscape of Localized Prostate Cancer | bioRxiv The Telomere Length Landscape of Localized Prostate Cancer View ORCID Profile Julie Livingstone , View ORCID Profile Yu-Jia Shiah , View ORCID Profile Takafumi N Yamaguchi , View ORCID Profile Lawrence E Heisler , Vincent Huang , View ORCID Profile Robert Lesurf , Erik Drysdale , Jeffrey Green , View ORCID Profile Theodorus van der Kwast , View ORCID Profile Robert G Bristow , View ORCID Profile Michael Fraser , View ORCID Profile Paul C Boutros doi: https://doi.org/10.1101/2021.05.22.445239 This article is a preprint and has not been certified by peer review [ Abstract Info/History Metrics Preview PDF Abstract Replicative immortality is a hallmark of cancer, and can be achieved through telomere lengthening and maintenance. We report telomere lengths (TLs) of 392 localized prostate cancer tumo

Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? | Prostate Cancer and Prostatic Diseases Review Article Published: 25 May 2021 Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs? Nicholas A. Zorko & Charles J. Ryan   Prostate Cancer and Prostatic Diseases ( 2021 ) Cite this article Metrics details Abstract Background Checkpoint inhibitors and currently approved cellula

New insights into androgen's action could boost battle against prostate cancer -- ScienceDaily sciencedaily.com New insights into androgen's action could boost battle against prostate cancer 4 minutes Researchers at UVA Cancer Center have unveiled important new insights into how hormones known as androgens act on our cells -- and the discovery could boost efforts to develop better treatments for prostate, ovarian and breast cancers. The findings shed light on how androgens interact with their receptors inside cells to affect gene activity. This process is important in both healthy cells and certain cancers. Hormone therapy for prostate cancer, for example, aims to reduce the amount of androgen in the body, or to stop it from fueling the cancer cells. However, the approach does not work for some men, and for others it eventually fails. So scientists are eager to better understa

18 F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review | Prostate Cancer and Prostatic Diseases Review Article Open Access Published: 19 May 2021 18 F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review Soroush Rais-Bahrami , Jason A. Efstathiou , Catriona M. Turnbull , Stephen B. Camper , Andy Kenwright , David M. Schuster & Andrew F. Scarsbrook   Prostate Cancer and Prostatic Diseases ( 2021 ) Cite this article 132 Accesses 4 Altmetric Metrics details

Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy - Wenzel - - The Prostate - Wiley Online Library Review Article Open Access Published: 19 May 2021 18 F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review Soroush Rais-Bahrami , Jason A. Efstathiou , Catriona M. Turnbull , Stephen B. Camper , Andy Kenwright , David M. Schuster & Andrew F. Scarsbrook   Prostate Cancer and Prostatic Diseases ( 2021 ) Cite this article 132 Accesses 4 Altmetric Metrics details

Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy - Corradi - - The Prostate - Wiley Online Library ORIGINAL ARTICLE Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy John P. Corradi PhD , Christine White Cumarasamy MD , Ilene Staff PhD , Joseph Tortora MS , Andrew Salner MD , Tara McLaughlin PhD , Joseph Wagner MD First published: 18 May 2021 https://doi.org/10.1002/pros.24150 Joseph Wagner serves on the speaker's bureau for Genomic Health and as a consultant for Covidien. Abstract Background Identification of novel biomarkers associated with high-risk prostate cancer or biochemical recurrence can drive improvement in detec

Avenda Health laser platform improves prostate cancer outcomes optics.org Avenda Health laser platform improves prostate cancer outcomes SPIE Europe Ltd 4-5 minutes 18 May 2021 FDA Breakthrough Device status allows priority review of clinical and commercial decisions. Laser-based prostate cancer treatment from California's Avenda Health has been granted Breakthrough Device status by the US FDA. The status, applied for by the company before approval by the FDA, provides Avenda with priority review for clinical trial protocols and commercialization decisions, and may also facilitate reimbursement through the US Medicare program as the platform translates into clinical use. The Avenda Health Focal Therapy System is intended to use patient-specific information and AI to allow controlled laser ablation of prostate tumors while protecting surrounding healthy tissues. "We see o

Physical activity decreases the risk of cancer reclassification in patients on active surveillance: a multicenter retrospective study | Prostate Cancer and Prostatic Diseases : Physical activity (PA) is associated with favorable outcomes in prostate cancer (PCa) patients. We assessed its effect on the risk of PCa reclassification (PCaR) during active surveillance. Anthropometric, demographic, and clinical data concerning men diagnosed with a low-risk PCa and initially managed with active surveillance at the two participating institutions were retrospectively collected. The Physical Activity Scale for the Elderly (PASE) was used for patients’ self-assessment of their daily exercise and their consequent stratification into three groups: sedentary (PASE ≤ 65), moderately active (65 < PASE < 125), active (PASE ≥ 125). Kaplan–Meier model was used to evaluate the predictive role of PA on PCaR, computed at 2, 5, 10 years after diagnosis; differences between lifestyle groups were assesse

Focal therapy for prostate cancer—ready to be a standard of care? | Prostate Cancer and Prostatic Diseases

Androgen deprivation therapy and acute kidney injury in prostate cancer: room for debate? | Prostate Cancer and Prostatic Diseases

PSA bounce, prognosis, and clues to the radiation response | Prostate Cancer and Prostatic Diseases

Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer | Prostate Cancer and Prostatic Diseases

The interplay of microbiota and hormone regulation in men with prostate cancer | Prostate Cancer and Prostatic Diseases

(1) Active Surveillance Patients International April 2021 Meeting With Rick Popert - YouTube

Radiotracer Use Boosts Prostate Cancer Outcomes | MedPage Today

SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer | Cancer Research

First of six FREE webinars on making well-informed prostate cancer decisions | THE "NEW" PROSTATE CANCER INFOLINK prostatecancerinfolink.net First of six FREE webinars on making well-informed prostate cancer decisions 3-4 minutes Posted on May 14, 2021 by Sitemaster On Wednesday, May 26, the Cancer Support Community together with Prostate Cancer International will be holding the first of a series of six FREE educational webinars for patients and family members. As we have become better at identifying the risk level of prostate cancer at the several major stages in what can be a long prostate cancer journey, it has become more and more important that patients learn how to work with their doctors to assess the risks associated with their disease before they take decisions about any immediate or later form of treatment. This series of

Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings - Sartor - - The Prostate - Wiley Online Library : Abstract Background The most common site of disease in metastatic castration‐resistant prostate cancer (mCRPC) is the bone. The ALSYMPCA study demonstrated that radium‐223 significantly improved overall survival (OS) in mCRPC patients with symptomatic bone metastases and without visceral metastases. However, administration requires a multidisciplinary approach and an infrastructure that supports coordination of care, which may differ by practice site. We aimed to evaluate practice patterns and treatment outcomes in patients with mCRPC treated at a community practice (CP) compared with those treated at an academic ce

Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer | Journal of Nuclear Medicine

What level of evidence will it take to move towards widespread adoption of transperineal prostate biopsy in the USA? | Prostate Cancer and Prostatic Diseases

The distinct role of ALDH1A1 and ALDH1A3 in the regulation of prostate cancer metastases | bioRxiv

First clinical trial of Lu-177-PSMA-617 in recurrent, hormone-sensitive men | THE "NEW" PROSTATE CANCER INFOLINK

Scientists launch search for genetic test to spot killer prostate cancer | Prostate cancer | The Guardian theguardian.com Scientists launch search for genetic test to spot killer prostate cancer Robin McKie 4-5 minutes Scientists have begun work to create a prostate cancer screening service for the UK. In a few years, middle-aged men could be tested to reveal their genetic susceptibility to the condition, with those deemed to be under significant threat of developing it being offered treatment or surgery. The service would tackle a disease that has become the nation’s most commonly diagnosed cancer and would parallel Britain’s breast cancer screening programme. Every year, more than 47,500 men are diagnosed with prostate cancer: 129 a day on average. More than 11,500 deaths from the disease occur each year, with one in eight men being diagnosed with prostate cancer at some time in thei